Evolution of Vaccines Formulation to Tackle the Challenge of Anti-Microbial Resistant Pathogens

Int J Mol Sci. 2023 Jul 27;24(15):12054. doi: 10.3390/ijms241512054.

Abstract

The increasing diffusion of antimicrobial resistance (AMR) across more and more bacterial species emphasizes the urgency of identifying innovative treatment strategies to counter its diffusion. Pathogen infection prevention is among the most effective strategies to prevent the spread of both disease and AMR. Since their discovery, vaccines have been the strongest prophylactic weapon against infectious diseases, with a multitude of different antigen types and formulative strategies developed over more than a century to protect populations from different pathogens. In this review, we review the main characteristics of vaccine formulations in use and under development against AMR pathogens, focusing on the importance of administering multiple antigens where possible, and the challenges associated with their development and production. The most relevant antigen classes and adjuvant systems are described, highlighting their mechanisms of action and presenting examples of their use in clinical trials against AMR. We also present an overview of the analytical and formulative strategies for multivalent vaccines, in which we discuss the complexities associated with mixing multiple components in a single formulation. This review emphasizes the importance of combining existing knowledge with advanced technologies within a Quality by Design development framework to efficiently develop vaccines against AMR pathogens.

Keywords: AMR; adjuvant; antigen; formulation; vaccine.

Publication types

  • Review

Grants and funding

This work was sponsored by GlaxoSmithKline Biologicals SA. Massimiliano Biagini, Francesco Berti, Domenico Maione, Maxime Denis and Daniela Stranges are employees of the GSK group of companies. Francesco Tognetti is a student at the University of Padova and participates in a post graduate studentship program at GSK.